Rodger Novak
2017
In 2017, Rodger Novak earned a total compensation of $3.4M as President at CRISPR Therapeutics AG, a 47% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $258,530 |
|---|---|
| Option Awards | $2,515,703 |
| Salary | $523,759 |
| Other | $75,202 |
| Total | $3,373,194 |
Novak received $2.5M in option awards, accounting for 75% of the total pay in 2017.
Novak also received $258.5K in non-equity incentive plan, $523.8K in salary and $75.2K in other compensation.
Rankings
In 2017, Rodger Novak's compensation ranked 3,152nd out of 14,666 executives tracked by ExecPay. In other words, Novak earned more than 78.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,152 out of 14,666 | 79th |
Division Manufacturing | 1,083 out of 5,768 | 81st |
Major group Chemicals And Allied Products | 297 out of 2,074 | 86th |
Industry group Drugs | 227 out of 1,730 | 87th |
Industry Biological Products, Except Diagnostic Substances | 43 out of 316 | 86th |
Source: SEC filing on April 30, 2019.
Novak's colleagues
We found four more compensation records of executives who worked with Rodger Novak at CRISPR Therapeutics AG in 2017.